Actavis Said to Have Spurned $15 Billion Offer

May 14 (Bloomberg) -- Actavis rejected a cash-and-stock offer from fellow generic drugmaker Mylan for $15 billion, deciding instead to pursue talks to take over Warner Chilcott, said people familiar with the matter. (Source: Bloomberg)
U.S. Companies Add 201K Jobs: ADP
01:08 - Bloomberg's Olivia Sterns and Erik Schatzker reports on today top news stories. They speak on “Bloomberg Markets.” (Source: Bloomberg)
  • ISM Non-Manufacturing Falls to Lowest Since Last April
  • Adrian Grenier: Entourage Film 'Fun Exciting Ride'
  • Vera Bradley Tumbles Sharply